2023 World Conference on Lung Cancer (Posters)-P2.01. An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC

P2.01. An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC - PDF(Abstract)

Back to course

Pdf Summary

The CONCORDE study is a phase Ib platform study that aims to assess novel agents in combination with conventional radiotherapy (RT) in non-small cell lung cancer (NSCLC) patients. The study utilizes an adaptive Bayesian model-based approach to dose escalation. Participants receive RT and are allocated to one of five study arms, with three of the arms also receiving consolidation durvalumab. The primary objective is to assess safety and determine the recommended phase II dose of each combination. As of March 2023, three arms of the study are open to recruitment across nine centers. Out of the 35 participants randomized, no dose limiting toxicities have been observed in the DNA damage response inhibitors (DDRi) arms. The trial continues to recruit, with one arm submitted and scheduled to open in May 2023. A parallel translational program is also in development to identify biomarkers of treatment response, toxicity, and the impact on the immune system. Biomarkers of interest include plasma toxicity markers, immune cell profiling, radiomics, and ctDNA. The study is a collaboration between the University of Leeds, CRUK, and AstraZeneca, and aims to provide insights into the use of novel therapies in combination with radiotherapy for NSCLC patients.

Asset Subtitle

Ashley Horne

Meta Tag

Speaker Ashley Horne

Topic Local-Regional NSCLC: Novel Therapies & Trials

Keywords

CONCORDE study

phase Ib platform study

novel agents

conventional radiotherapy

non-small cell lung cancer

adaptive Bayesian model-based approach

dose escalation

consolidation durvalumab

safety assessment

recommended phase II dose